Özet:

Chronic myeloid leukemia (KML) is a malignant clonal hematopoetic disease. BCR-ABL1 is a fusion gen and plays a role in the molecular pathogenesis of KML. This protein is a thyrozine kinase code. The modulators of this tirosine kinase, which influences ACT, ERK, STAT pathways, are GAB2 and GRB2. The STI571 (imatinib mesilate) is a thyrozine kinase inhibitor contained in the treatment protocol of KML. Genistein is a plant flavonoid with estrogenic properties as well as thyrocin kinase inhibitor activity. In this study, human KML cell series K562 cells, along with the application of STI571, aimed at determining the effect of the application of genistein on the cellular signal trails at the protein level. Method: The K562 cells are multiplied under standard conditions. The cytotoxic dose of STI571 and genistein was determined by the MTT test. STI571 and genistein were applied for 24 and 48 hours in a single and joint way. Protein levels are determined by the ELISA method. The results were statistically evaluated. The findings: The data were found that when collectively evaluated, the application of STI571 and genistine alone or together did not cause any significant change in protein levels. The result: In this study, the effects of genistine along with STI571 were evaluated on a wide protein panel. The characteristics of STI571 and genistein are known as the thyrozine kinase inhibitor. However, studies that study the effects of both agents on protein levels have controversial findings. According to our findings, the combination of both agents does not make a significant difference in protein levels.